ArticleERJ open research2024

AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.

Klaus F Rabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.